Mesoblast to buy stem cell business from Osiris
11 October, 2013 by Dylan Bushell-EmblingMesoblast (ASX:MSB) will pay up to US$100m to acquire the mesenchymal precursor cell business of US-based Osiris Therapeutics.
AusBiotech Annual Report 2013 shows year of solid delivery
10 October, 2013The AusBiotech Annual Report 2013 has been released, detailing another solid performance for AusBiotech and showing how it has delivered for its members and the Australian biotechnology industry. AusBiotech was steadfast in its advocacy and active in its representation and support of the industry, delivering a number of achievements in policy terms.
Strong results from PolyNovo's NovoSorb BTM trial
10 October, 2013 by Dylan Bushell-EmblingCalzada's (ASX:CZD) PolyNovo said its NovoSorb BTM dermal scaffold was well tolerated and effective during a 10-patient trial involving its use in free-flap donor site repair.
CSL to pay US$64m to settle class action suit
10 October, 2013 by Dylan Bushell-EmblingCSL (ASX:CSL) has negotiated a proposed settlement to a US class action antitrust lawsuit centred around the company's control of supply of plasma-derived protein therapeutics.
QRxPharma to refile MoxDuo NDA next month
09 October, 2013 by Dylan Bushell-EmblingAfter a positive meeting with the US FDA, QRxPharma (ASX:QRX) aims to resubmit its application for approval of pain drug MoxDuo in mid-November.
Eight more surgeons approved to use Allied's CardioCel in adults
08 October, 2013Eight surgeons, based at The Prince Charles Hospital in Brisbane, were today approved to use Allied Healthcare's (ASX: AHZ) CardioCel to repair and treat heart defects in adult patients under the Authorised Prescriber Scheme (APS).
Melbourne to host prestigious International Biotechnology Symposium
08 October, 2013In a major coup for the biotechnology industry and Australia, the International Biotechnology Symposium (IBS), a premier international conference in the rapidly growing field of biotechnology, is heading to Melbourne in 2016.
TranScrip Partners opens Hong Kong office
08 October, 2013UK-headquartered contract organisation TranScrip Partners has opened a new office in Hong Kong. This follows recent openings in Australia and the US and is underpinned by the continuing increase of contracts in the Asia-Pacific region.
ResMed nominates new director
04 October, 2013 by Dylan Bushell-EmblingResMed (ASX:RMD) has nominated US health sector veteran Carol J Burt to take long-serving director Michael Quinn's place on the board once his final term expires.
Facing the challenges of the agriculture, food, water and energy nexus
03 October, 2013On the premise that by 2050 the world will have a population of nine billion people, the OECD has declared a need to address the energy, water, food and agriculture nexus. More than 100 people gathered recently to discuss the role of biotechnology in addressing these issues and opportunities in food production.
pSivida licensee expects NHS listing in November
02 October, 2013 by Dylan Bushell-EmblingThe UK's NICE has issued a final draft recommendation in favour of reimbursement for pSivida (ASX:PVA) licensee Alimera Sciences' Iluvien in a subgroup of DME patients.
AusBiotech members invited to vote for board
01 October, 2013Online voting for the 2013 AusBiotech board election ballot is now open. The board has two positions available for election.
Bioniche posts last results before animal health sale
30 September, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) has reported its FY13 results and completed a Canadian equity offering and private placement to raise C$9.8m.
New CEO for Medical Technology Association of Australia
30 September, 2013The Medical Technology Association of Australia Limited has appointed Susanne Tegen as its new chief executive officer.
First Parkinson's patient implanted with LCT's NTCELL
27 September, 2013 by Dylan Bushell-EmblingThe first Parkinson's patient has been implanted with Living Cell Technologies' (ASX:LCT) NTCELL regenerative treatment during a phase I trial.
